What Is P21 (P021) Peptide? CNTF-Derived Neurogenesis Research

P21, also written P021, is a small synthetic peptidergic compound derived from a biologically active region of ciliary neurotrophic factor (CNTF), chemically modified for stability and blood–brain-barrier penetration and studied in laboratory models of neurogenesis and neurodegeneration. Its core sequence (Ac–DGGLAG–NH₂) is derived from the most active region of CNTF, with an adamantane group added to improve durability and lipophilicity. P21 is a research-only compound. It is not a drug, not a supplement, and not approved for human use. All findings described below come from in-vitro and animal studies only.

Quick facts

• Class: CNTF-derived neurotrophic peptidergic compound (small synthetic peptide)
• Also written: P021
• Core sequence: Ac–DGGLAG–NH₂, with a C-terminal adamantane modification
• Research focus: adult neurogenesis and neurotrophin (BDNF) research in cell and animal models

What is P21?

P21 (P021) is a synthetic peptidergic compound engineered from the biologically active region of human ciliary neurotrophic factor (CNTF), a naturally occurring protein involved in the survival and maintenance of nerve cells. Rather than using the full CNTF protein — which is large and unstable — researchers identified a short active fragment through epitope mapping and built a much smaller molecule around it. A γ-aminoadamantane group was added at the C-terminus, an adamantane modification intended to reduce enzymatic degradation and improve the compound’s ability to cross the blood–brain barrier in laboratory models. The result is a compact, more stable molecule used as a tool to study CNTF-related signaling.

What does the research show?

P21 has been characterized primarily in rodent models. In an early study in normal adult mice, peripherally administered P21 was associated with enhanced neurogenesis and maturation of newly born neurons in the dentate gyrus of the hippocampus (Li et al., 2010). In a transgenic Alzheimer’s-model mouse, researchers reported that P21 was associated with changes in dendritic and synaptic markers and measures of hippocampal neurogenesis (Baazaoui & Iqbal, 2017). Importantly, results are not uniform across models: in a more recent in-vitro and in-vivo study of CDKL5 deficiency disorder, P21 restored several deficits in cultured human neuronal cells but did not raise BDNF levels or reproduce the same neuroanatomical effects in the knockout mice (Mottolese et al., 2024). These mixed findings are typical of an early-stage research compound and are not evidence of any effect in humans.

Mechanisms studied in the lab

• CNTF-mimetic signaling: P21 is designed to engage pathways associated with the CNTF active region it is derived from.
• BDNF modulation: in some rodent models, P21 has been associated with increased brain-derived neurotrophic factor (BDNF) expression — though this was not observed in every model.
• Neurogenesis in models: studied as a tool for probing adult hippocampal neurogenesis and synaptic plasticity in cell and animal systems.

Research status

P21/P021 is a preclinical research compound. The available literature consists of in-vitro experiments and animal studies, and there are no established human clinical trials demonstrating safety or efficacy. P21 is not approved by the FDA or any regulatory agency for the diagnosis, treatment, cure, or prevention of any condition. It is intended strictly for laboratory research use only and is not for human or veterinary use.

Related research peptides

P21 is one of several compounds studied in central-nervous-system research. Browse the full research peptide catalog for in-stock items. Two related CNS-focused research peptides with their own educational guides are Semax and Selank, both studied in neuropeptide and BDNF-related research contexts.

FAQ

Is P21 the same as P021? Yes. “P21” and “P021” refer to the same CNTF-derived peptidergic compound; the naming simply varies across publications and vendors.

Is P21 approved for human use? No. P21 is a research-use-only compound. It has not been approved by the FDA and is not intended for human consumption, treatment, or supplementation.

What has P21 mainly been studied for? In published research, P21 has been used as a laboratory tool to investigate adult neurogenesis, BDNF-related neurotrophin signaling, and synaptic plasticity in cell cultures and rodent models — not as a therapy.

References

1. Li B, et al. Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice. FEBS Lett. 2010.
2. Baazaoui N, Iqbal K. Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound. Alzheimers Res Ther. 2017.
3. Mottolese N, et al. Effects of a CNTF small-molecule peptide mimetic in a model of CDKL5 deficiency disorder. J Neurodev Disord. 2024.

For research use only. P21 (P021) is not a supplement, drug, or device; not FDA-approved; not for human or veterinary use. Statements have not been evaluated by the FDA.